BIXT
Bioxytran, Inc
$0.02
0.00 (-13.54%)
At close · Jul 2
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue operations.”View the 10-Q filed May 15, 2026
Market Cap
$2.84M
Shares
114,195,220
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.02
Open$0.03
Day$0.02–0.03
52W$0.02–0.10
Avg vol 30d44K
Short int14K · 0.0% float · 1.0d
Short vol29%
DataJan 2020–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Strong Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−52% below
−
Price vs 50-day avg
−21% below
◦
RSI (14)
39 · neutral
−
MACD trend
negative
−
52-week position
1% · near low
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $0 › 200d $0 — 200d above 50d
◦
Institutional flow
No 13F holder data
◦
Insider flow
No net insider activity over 90 days
+
Short interest
0.01% of float · ▼ -0.1% MoM · 1.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
No 13F holder history
Fundamentals
Strong
−
Revenue growth
−22% Y/Y
+
Gross margin
46%, contracting
◦
EPS growth
0% Y/Y
+
Balance sheet
net cash $11.1K
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−52% below
Bearish
Price vs 50-day avg
−21% below
Bearish
RSI (14)
39 · neutral
Neutral
MACD trend
negative
Bearish
52-week position
1% · near low
Bearish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.01% of float · ▼ -0.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
52-wk low $0
Now $0 · 1%
52-wk high $0
vs 200-day avg -52%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIXT
this stock
Bioxytran, Inc
|
$2.84M | -67.2% | -22.5% | — | 0.0% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIXT | -12.3% | -17.0% | -66.4% | -4.2% | -67.2% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -13.8% | -15.8% | -74.4% | -4.0% | -76.4% |